Circle of wilis

Reading File
Finding Sources
Searching the Web

Circle of Willis anatomy components clinical significance

Reading File
Finding Sources
Loading Image
Reading File
Reading File
Here is a thorough overview of the Circle of Willis drawn from authoritative medical textbooks:

Circle of Willis (Circulus Arteriosus)

Circle of Willis and Its Main Branches
Figure: Circle of Willis and its main branches, inferior view of the brain - Neuroanatomy through Clinical Cases, 3rd Ed.

Definition & Location

The Circle of Willis is an anastomotic ring of arteries at the base of the brain, encircling the stalk of the pituitary gland. It connects the two major arterial systems supplying the brain:
  1. The anterior circulation - from the bilateral internal carotid arteries (ICAs)
  2. The posterior circulation - from the bilateral vertebral arteries (which join to form the basilar artery)

Components

The ring is formed by the following vessels (anterior to posterior):
VesselAbbreviationOrigin
Anterior cerebral arteries (×2)ACATerminal branches of ICA
Anterior communicating arteryACommConnects the two ACAs
Internal carotid arteries (×2)ICACommon carotid arteries
Posterior communicating arteries (×2)PCommConnects ICA to PCA
Posterior cerebral arteries (×2)PCATerminal branches of basilar artery
The basilar artery (formed by the union of the two vertebral arteries) supplies the posterior part of the ring via the PCAs.
A useful mnemonic for the branches of the supraclinoid ICA: OPAAM - Ophthalmic, Posterior communicating, Anterior choroidal, Anterior cerebral, Middle cerebral arteries.

The Three Main Cerebral Arteries

All arise from or near the Circle of Willis:
  • ACA - sweeps forward and over the corpus callosum in the interhemispheric fissure; supplies the medial frontal and parietal cortex (including the leg area of the motor/sensory cortex)
  • MCA - turns laterally into the Sylvian fissure; supplies the lateral cerebral hemisphere (face, arm, language areas)
  • PCA - arises from the top of the basilar artery; supplies the occipital lobe and posterior temporal lobe (visual cortex)
Deep structures (basal ganglia, thalamus, internal capsule) are supplied by small penetrating (perforating) branches arising near the circle, not from its main ring vessels.

Collateral Function

The primary physiological role of the Circle of Willis is collateral blood flow. If one vessel is occluded or damaged (e.g., by stroke, aneurysm rupture, or carotid endarterectomy), the ring allows blood to be rerouted from the intact circulation to the affected region.
"The Circle of Willis provides extensive collateral circulation, connecting the right and left carotid arteries to each other and each to the vertebrobasilar system." - Schwartz's Principles of Surgery, 11th Ed.

Anatomical Variants - Clinically Important

A complete, full-caliber Circle of Willis is present in only ~34% of individuals (Neuroanatomy through Clinical Cases, 3rd Ed.). Common variants include:
  • Hypoplastic PComm - most common variant; reduces posterior-to-anterior collateral flow
  • Fetal-type PCA - the PCA arises directly from the ICA rather than the basilar artery (~20-30% of people)
  • Absent AComm - eliminates cross-flow between the two ACAs
  • Hypoplastic A1 segment - reduces collateral from the contralateral ACA
Autopsy studies confirm that the majority of specimens have anatomical anomalies - clinically relevant when planning carotid endarterectomy or assessing stroke risk.

Internal Carotid Artery Segments (en route to the Circle)

The ICA passes through several named segments before reaching the Circle:
  1. Cervical segment - vertical, in the neck
  2. Petrous segment - enters the carotid canal of the temporal bone
  3. Cavernous segment - S-shaped "carotid siphon" within the cavernous sinus
  4. Supraclinoid (intracranial) segment - pierces the dura; gives off the main branches

Clinical Significance

ConditionRelevance to Circle of Willis
Berry (saccular) aneurysmsForm at bifurcation points within the CoW (especially AComm, PComm, MCA bifurcation); rupture causes subarachnoid hemorrhage
Ischemic strokeCollateral flow through the CoW may limit infarct size in carotid/MCA occlusion
Carotid endarterectomyDuring carotid clamping, the brain relies entirely on contralateral flow via the CoW
Carotid artery diseaseComplete occlusion proximal to the CoW may be tolerated if the ring is complete
CN III palsyA PComm aneurysm compresses the oculomotor nerve (CN III runs nearby) causing a "surgical" CN III palsy with pupil dilation

Collateral Sources Beyond the CoW

The Circle of Willis is the primary collateral pathway, but other systems also contribute:
  1. Anastomoses between extracranial and intracranial arteries (e.g., ophthalmic artery)
  2. Leptomeningeal anastomoses between terminal branches of the ACA, MCA, and PCA

Sources: Neuroanatomy through Clinical Cases, 3rd Ed.; Medical Physiology (Boron & Boulpaep); Schwartz's Principles of Surgery, 11th Ed.; Localization in Clinical Neurology, 8th Ed.; Grainger & Allison's Diagnostic Radiology

Autoimmune enchephalitus

Finding Sources
Searching PubMed

autoimmune encephalitis diagnosis treatment

Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Here is a thorough, textbook-based overview of Autoimmune Encephalitis:

Autoimmune Encephalitis


Definition & Epidemiology

Autoimmune encephalitis (AE) is an inflammatory brain condition caused by misdirected immune responses targeting neuronal and glial cell-surface or intracellular antigens. It is increasingly recognized as a treatable cause of brain dysfunction distinct from infectious encephalitis.
  • Accounts for approximately 25% of all encephalitis cases (Goldman-Cecil Medicine)
  • The overall incidence of autoimmune encephalitis (paraneoplastic + non-paraneoplastic) is now similar to that of infectious encephalitis
  • Can be triggered by immune checkpoint inhibitors (e.g., anti-PD-1 drugs)

Classification

AE is broadly divided into two categories based on antigen location:

1. Antibodies Against Intracellular Antigens (High-risk for cancer)

  • Pathogenesis: CD4+ and CD8+ T-cell infiltrates mediate cytotoxicity; antibodies cannot reach epitopes
  • Often poor response to immunotherapy; neuronal loss is extensive
  • Associated with specific tumors (see table below)

2. Antibodies Against Neuronal Cell-Surface/Synaptic Antigens (Low-to-intermediate cancer risk)

  • Pathogenesis: Antibodies have direct access to their target, altering receptor function (e.g., cross-linking, internalization, blocking)
  • Generally respond better to immunotherapy
  • NMDA-R antibodies are the classic example
"In encephalitis with antibodies against surface antigens, the antibodies have access to the epitopes and can potentially alter the structure and function of the antigen." - Harrison's Principles of Internal Medicine, 22nd Ed.

Key Antibodies, Syndromes & Tumor Associations

Neural AntigenAssociated TumorClinical Phenotype
Hu (ANNA-1)Small cell lung carcinoma (SCLC)Limbic / encephalomyelitis, sensory neuronopathy
Yo (PCA-1)Ovary, breastRapidly progressive cerebellar syndrome
Ri (ANNA-2)Breast, gynecologic, SCLCCerebellar degeneration, opsoclonus
Ma2Testicular seminomaLimbic + brainstem encephalitis
CRMP5 (CV2)SCLC, thymomaEncephalomyelitis, chorea, optic neuritis
NMDA-ROvarian teratoma (or no tumor)Psychosis, dyskinesias, autonomic instability
AMPA-RThymoma, SCLCLimbic encephalitis with relapses
GABA-A receptorThymoma (infrequent)Limbic encephalitis
GABA-B receptorSCLCLimbic encephalitis
LGI1Neuroendocrine tumor (rarely)Faciobrachial dystonic seizures, limbic encephalitis
CASPR2ThymomaEncephalitis, Morvan syndrome, neuromyotonia
GAD65Thymoma, SCLC, diabetesCerebellar encephalitis, stiff-person syndrome
mGluR5Hodgkin lymphomaEncephalitis (Ophelia syndrome)
DPPXB-cell lymphomaHyperekplexia, encephalitis
IgLON5None typicallySleep disorder, brainstem encephalitis
GlyR (glycine receptor)Thymoma (infrequent)Limbic encephalitis, PERM

Clinical Syndromes

Three main clinical presentations:
  1. Limbic encephalitis - memory loss, confusion, behavioral changes, temporal lobe seizures, medial temporal T2/FLAIR signal on MRI
  2. NMDA-receptor encephalitis - the most common form; subacute psychiatric prodrome → seizures → movement disorders (orofacial dyskinesias, choreoathetosis) → autonomic instability → decreased consciousness
  3. Brainstem encephalitis - diplopia, dysphagia, nystagmus, respiratory failure
General features (onset subacute, usually < 3 months):
  • Progressive cognitive decline and memory deficits
  • Behavioral and psychiatric changes (often misdiagnosed as primary psychiatric illness)
  • Seizures
  • Abnormal movements: orofacial dyskinesias, faciobrachial dystonic seizures (LGI1-specific)
  • Autonomic dysfunction (especially NMDA-R)
  • Focal deficits: aphasia, dysarthria, ataxia

Anti-NMDA Receptor Encephalitis - Spotlight

The most common autoimmune encephalitis, now thought to be the most common cause of autoimmune encephalopathy overall.
  • Antibody target: GluN1 subunit of NMDA receptor
  • Demographics: Female predominance; young women and girls
  • Tumor association: Ovarian teratoma (search mandatory), though many cases are tumor-free
  • Stages: Psychiatric prodrome → seizures → movement disorders/dyskinesias → autonomic instability → decreased consciousness/coma
  • Can follow herpes simplex encephalitis as a post-infectious autoimmune reaction
  • Diagnosis: Antibody detection in CSF is more reliable than serum (false-negatives in serum common)
  • MRI: May be normal or show focal encephalitis

Diagnostic Work-Up

  1. Exclude infectious encephalitis - blood and CSF microbiology, HSV PCR
  2. Brain MRI with contrast - detect typical patterns (medial temporal signal, diffuse cortical changes); exclude mimics
  3. CSF analysis - lymphocytic pleocytosis (5-100 cells/μL), elevated protein; send for antibody panel
  4. Serum antibody panel (send both serum AND CSF for best yield): NMDA-R, AMPA-R, GABA-A/B-R, LGI1, CASPR2, GAD65, DPPX, IgLON5, mGluR1, GlyR, MOG
  5. Cancer screening - CT chest/abdomen/pelvis, FDG-PET; pelvic ultrasound/MRI for ovarian teratoma; testicular ultrasound if Ma2+
  6. EEG - can show extreme delta brush pattern (pathognomonic association with NMDA-R encephalitis)
  7. Exclude toxic/metabolic causes in parallel; consider primary psychiatric diagnoses

Treatment

No single standardized regimen exists, but expert consensus guides the following stepwise approach:

First-Line

AgentRegimen
IV methylprednisolone1000 mg/day IV x 5 days
IV immunoglobulin (IVIg)400 mg/kg every other day x 5 days (if steroids not tolerated)
Plasma exchange (PLEX)For refractory or contraindicated cases

Second-Line (if poor response)

AgentRegimen
Rituximab1000 mg IV x 2 doses, 2 weeks apart
Tocilizumab4 mg/kg IV every 4 weeks (anti-IL-6 receptor)
CyclophosphamideAnecdotal reports

Maintenance

  • Weekly methylprednisolone or IVIg for 6-12 weeks as outpatient
  • Long-term: azathioprine, mycophenolate, methotrexate

Tumor removal

  • If an underlying tumor is found (teratoma, SCLC, thymoma), prompt tumor treatment is essential and often leads to neurologic improvement
"Treatment for autoimmune encephalitis should be initiated as early as feasible, as the disease carries a high risk of morbidity." - Adams and Victor's Principles of Neurology, 12th Ed.

Prognosis

  • Varies widely depending on antibody type, presence of tumor, and speed of treatment initiation
  • Cell-surface antigen antibodies (NMDA-R, LGI1, CASPR2) - generally better prognosis with treatment
  • Intracellular antigen antibodies (Hu, Yo, Ri) - poor prognosis; neuronal death is irreversible
  • Early treatment hastens recovery and reduces disability and relapse risk
  • Relapse can occur; long-term immunosuppression may be needed

Recent Evidence (2026)

A 2026 systematic review (PMID 41499723) specifically examined seronegative autoimmune encephalitis (where no antibody is identified), characterizing its clinical features - an important reminder that up to ~50% of AE cases may be antibody-negative, and clinical criteria (Graus 2016 criteria) remain key.

Sources: Goldman-Cecil Medicine; Harrison's Principles of Internal Medicine, 22nd Ed.; Adams and Victor's Principles of Neurology, 12th Ed.; Bradley and Daroff's Neurology in Clinical Practice

Pdf

Reading File
Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "created"

Running Command

mkdir -p /tmp/workspace/autoimmune-encephalitis && cat > /tmp/workspace/autoimmune-encephalitis/generate_pdf.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm from reportlab.lib import colors from reportlab.platypus import ( SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, KeepTogether ) from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY OUTPUT = "/tmp/workspace/autoimmune-encephalitis/Autoimmune_Encephalitis.pdf" doc = SimpleDocTemplate( OUTPUT, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2.2*cm, bottomMargin=2.2*cm, title="Autoimmune Encephalitis", author="Orris Medical Library" ) W = A4[0] - 4*cm # usable width # ── Colour palette ────────────────────────────────────────────────────────── DARK_BLUE = colors.HexColor("#1a3a5c") MED_BLUE = colors.HexColor("#2563a8") LIGHT_BLUE = colors.HexColor("#dbeafe") ACCENT = colors.HexColor("#0e7490") LIGHT_TEAL = colors.HexColor("#e0f2f1") WARN_AMBER = colors.HexColor("#fef3c7") WARN_BORDER = colors.HexColor("#d97706") LIGHT_GRAY = colors.HexColor("#f8fafc") TABLE_HEAD = colors.HexColor("#1e40af") TABLE_ALT = colors.HexColor("#eff6ff") HR_COLOR = colors.HexColor("#94a3b8") styles = getSampleStyleSheet() def style(name, **kw): s = ParagraphStyle(name, **kw) return s TITLE_S = style("Title2", fontSize=22, leading=28, textColor=DARK_BLUE, fontName="Helvetica-Bold", spaceAfter=4, alignment=TA_CENTER) SUBTITLE_S = style("Sub", fontSize=11, leading=14, textColor=MED_BLUE, fontName="Helvetica", spaceAfter=2, alignment=TA_CENTER) SOURCE_S = style("Src", fontSize=8, leading=10, textColor=colors.HexColor("#64748b"), fontName="Helvetica-Oblique", alignment=TA_CENTER, spaceAfter=12) H1 = style("H1", fontSize=14, leading=18, textColor=colors.white, fontName="Helvetica-Bold", spaceBefore=14, spaceAfter=4, leftIndent=8, rightIndent=8, backColor=DARK_BLUE, borderPad=5) H2 = style("H2", fontSize=11, leading=14, textColor=DARK_BLUE, fontName="Helvetica-Bold", spaceBefore=10, spaceAfter=3, borderPad=3, backColor=LIGHT_BLUE, leftIndent=4) H3 = style("H3", fontSize=10, leading=13, textColor=ACCENT, fontName="Helvetica-Bold", spaceBefore=7, spaceAfter=2) BODY = style("Body2", fontSize=9.5, leading=14, textColor=colors.HexColor("#1e293b"), fontName="Helvetica", spaceAfter=4, alignment=TA_JUSTIFY) BULLET = style("Bul", fontSize=9.5, leading=14, textColor=colors.HexColor("#1e293b"), fontName="Helvetica", leftIndent=16, firstLineIndent=-10, spaceAfter=3) BULLET2 = style("Bul2", fontSize=9, leading=13, textColor=colors.HexColor("#334155"), fontName="Helvetica", leftIndent=28, firstLineIndent=-10, spaceAfter=2) NOTE_S = style("Note", fontSize=8.5, leading=12, textColor=colors.HexColor("#374151"), fontName="Helvetica-Oblique", leftIndent=10, rightIndent=10, spaceAfter=4, backColor=WARN_AMBER, borderColor=WARN_BORDER, borderWidth=0.5, borderPad=6) def b(t): return f"<b>{t}</b>" def i(t): return f"<i>{t}</i>" def bullet_item(text): return Paragraph(f"• {text}", BULLET) def bullet2(text): return Paragraph(f"◦ {text}", BULLET2) def h1(text): return Paragraph(text, H1) def h2(text): return Paragraph(text, H2) def h3(text): return Paragraph(text, H3) def body(text): return Paragraph(text, BODY) def sp(h=6): return Spacer(1, h) def hr(): return HRFlowable(width="100%", thickness=0.5, color=HR_COLOR, spaceAfter=4, spaceBefore=4) def note(text): return Paragraph(text, NOTE_S) def make_table(headers, rows, col_widths=None, alt_color=TABLE_ALT): data = [headers] + rows if col_widths is None: col_widths = [W / len(headers)] * len(headers) hdr_style = ParagraphStyle("TH", fontSize=8.5, fontName="Helvetica-Bold", textColor=colors.white, leading=11, alignment=TA_CENTER) cell_style = ParagraphStyle("TD", fontSize=8, fontName="Helvetica", textColor=colors.HexColor("#1e293b"), leading=11, alignment=TA_LEFT) fmt_data = [] for ri, row in enumerate(data): fmt_row = [] for ci, cell in enumerate(row): s = hdr_style if ri == 0 else cell_style fmt_row.append(Paragraph(str(cell), s)) fmt_data.append(fmt_row) ts = TableStyle([ ("BACKGROUND", (0,0), (-1,0), TABLE_HEAD), ("ROWBACKGROUNDS", (0,1), (-1,-1), [colors.white, alt_color]), ("GRID", (0,0), (-1,-1), 0.4, colors.HexColor("#cbd5e1")), ("VALIGN", (0,0), (-1,-1), "MIDDLE"), ("TOPPADDING", (0,0), (-1,-1), 4), ("BOTTOMPADDING", (0,0), (-1,-1), 4), ("LEFTPADDING", (0,0), (-1,-1), 5), ("RIGHTPADDING", (0,0), (-1,-1), 5), ("LINEBELOW", (0,0), (-1,0), 1, DARK_BLUE), ("ROWBACKGROUNDS", (0,0), (-1,0), [TABLE_HEAD]), ]) t = Table(fmt_data, colWidths=col_widths, repeatRows=1, hAlign="LEFT") t.setStyle(ts) return t # ════════════════════════════════════════════════════════════════════════════ story = [] # ── TITLE BLOCK ───────────────────────────────────────────────────────────── story += [ sp(10), Paragraph("Autoimmune Encephalitis", TITLE_S), Paragraph("A Comprehensive Clinical Reference", SUBTITLE_S), Paragraph("Sources: Goldman-Cecil Medicine · Harrison's Principles (22nd Ed.) · Adams & Victor's Neurology (12th Ed.) · Bradley & Daroff's Neurology", SOURCE_S), hr(), sp(4), ] # ── 1. DEFINITION & EPIDEMIOLOGY ──────────────────────────────────────────── story += [ h1("1. Definition & Epidemiology"), body("Autoimmune encephalitis (AE) is an inflammatory brain condition caused by misdirected immune responses targeting <b>neuronal and glial cell-surface or intracellular antigens</b>. It is increasingly recognized as a treatable cause of brain dysfunction distinct from infectious encephalitis."), sp(4), ] epi_items = [ "Accounts for approximately <b>25%</b> of all encephalitis cases", "Overall incidence of AE (paraneoplastic + non-paraneoplastic) is now <b>similar to that of infectious encephalitis</b>", "Can be triggered by <b>immune checkpoint inhibitors</b> (e.g., anti-PD-1 / anti-CTLA-4 drugs)", "Affects <b>2–3%</b> of patients with neuroblastoma or SCLC; <b>30–50%</b> of patients with thymoma may develop paraneoplastic AE", "NMDA-R encephalitis shows a <b>female predominance</b> and commonly affects young women and girls", ] for item in epi_items: story.append(bullet_item(item)) story.append(sp(6)) # ── 2. PATHOGENESIS ────────────────────────────────────────────────────────── story += [ h1("2. Pathogenesis"), body("AE is divided into two categories based on antigen location. The distinction is clinically important as it determines cancer risk, treatment response, and prognosis."), sp(4), h2("2a. Antibodies Against Intracellular Antigens (High cancer risk >70%)"), ] for item in [ "Antibodies <b>cannot reach</b> the intracellular epitopes", "Cytotoxic <b>CD4+ and CD8+ T-cell</b> infiltrates mediate neuronal death", "T cells make direct contact with neurons; perforin/granzyme mechanisms cause degeneration", "Extensive neuronal loss and gliosis on pathology", "Generally <b>poor response to immunotherapy</b> — neuronal death is irreversible", "Examples: Hu, Yo, Ri, Ma2, CRMP5 (CV2), amphiphysin antibodies", ]: story.append(bullet_item(item)) story += [ sp(4), h2("2b. Antibodies Against Cell-Surface / Synaptic Antigens (Low-to-intermediate cancer risk)"), ] for item in [ "Antibodies have <b>direct access</b> to target antigens on living neurons", "Alter receptor function via cross-linking, internalization, or functional blockade", "Moderate brain inflammatory infiltrates; less neuronal loss", "Generally <b>respond well to immunotherapy</b>", "Examples: NMDA-R, LGI1, CASPR2, AMPA-R, GABA-A/B-R, DPPX, mGluR5", ]: story.append(bullet_item(item)) story.append(sp(6)) # ── 3. ANTIBODY TABLE ──────────────────────────────────────────────────────── story += [ h1("3. Key Antibodies, Syndromes & Tumor Associations"), sp(4), ] ab_headers = [b("Antibody"), b("Tumor Association"), b("Clinical Phenotype")] ab_rows = [ ["Hu (ANNA-1)", "SCLC", "Limbic encephalitis, sensory neuronopathy, encephalomyelitis"], ["Yo (PCA-1)", "Ovary, breast", "Rapidly progressive cerebellar syndrome"], ["Ri (ANNA-2)", "Breast, gynecologic, SCLC", "Cerebellar degeneration, opsoclonus, brainstem encephalitis"], ["Ma2", "Testicular seminoma", "Limbic + hypothalamic + brainstem encephalitis"], ["CRMP5 (CV2)", "SCLC, thymoma", "Encephalomyelitis, chorea, optic neuritis, peripheral neuropathy"], ["NMDA-R", "Ovarian teratoma (or none)", "Psychosis, dyskinesias, autonomic instability, coma"], ["AMPA-R", "Thymoma, SCLC", "Limbic encephalitis with relapses"], ["GABA-A receptor", "Thymoma (infrequent)", "Limbic encephalitis, refractory seizures"], ["GABA-B receptor", "SCLC", "Limbic encephalitis"], ["LGI1", "Neuroendocrine (rarely)", "Faciobrachial dystonic seizures, limbic encephalitis, hyponatremia"], ["CASPR2", "Thymoma", "Morvan syndrome, neuromyotonia, encephalitis (IgG4 isotype)"], ["GAD65", "Thymoma, SCLC, diabetes", "Cerebellar encephalitis, stiff-person syndrome"], ["mGluR5", "Hodgkin lymphoma", "Ophelia syndrome (encephalitis + psychosis)"], ["DPPX", "B-cell lymphoma", "Hyperekplexia, diarrhea, encephalitis"], ["IgLON5", "None typically", "Sleep disorder, brainstem encephalitis, tauopathy"], ["GlyR", "Thymoma (infrequent)", "Limbic encephalitis, PERM (progressive encephalomyelitis with rigidity)"], ] cw = [2.5*cm, 3.8*cm, 9.4*cm] story.append(make_table(ab_headers, ab_rows, col_widths=cw)) story.append(sp(6)) # ── 4. CLINICAL FEATURES ───────────────────────────────────────────────────── story += [ h1("4. Clinical Presentations"), body("Onset is typically <b>subacute</b> (< 3 months). Three main clinical syndromes are recognized:"), sp(4), h2("4a. Limbic Encephalitis"), ] for item in [ "Memory loss (hippocampal involvement), confusion, disorientation", "Behavioral and personality changes", "Temporal lobe seizures", "MRI: medial temporal lobe T2/FLAIR hyperintensity", "Associated antibodies: LGI1, CASPR2, AMPA-R, GABA-B-R, Hu, Ma2", ]: story.append(bullet_item(item)) story += [sp(4), h2("4b. NMDA-Receptor Encephalitis (most common form)")] for item in [ "<b>Stage 1 (Prodrome):</b> fever, headache, viral-like illness (days)", "<b>Stage 2 (Psychiatric):</b> psychosis, agitation, bizarre behaviour, insomnia — often misdiagnosed", "<b>Stage 3 (Unresponsive/Catatonic):</b> decreased consciousness, mutism", "<b>Stage 4 (Hyperkinetic):</b> orofacial dyskinesias, choreoathetosis, stereotyped movements", "<b>Stage 5 (Autonomic):</b> hyperthermia, tachycardia, BP instability, hypoventilation", "EEG: <b>extreme delta brush</b> pattern (pathognomonic association)", "CSF antibody testing more reliable than serum (false-negatives in serum common)", ]: story.append(bullet_item(item)) story += [sp(4), h2("4c. Brainstem Encephalitis")] for item in [ "Diplopia, dysphagia, dysarthria, nystagmus", "Respiratory failure may require ICU admission", "Associated antibodies: Ri, Ma2, CASPR2, GABA-B-R", ]: story.append(bullet_item(item)) story += [ sp(4), h2("4d. Other Specific Syndromes"), bullet_item("<b>Faciobrachial dystonic seizures (FBDS)</b> — pathognomonic for LGI1; brief, frequent, ipsilateral face+arm jerks; precede limbic encephalitis"), bullet_item("<b>Cerebellar ataxia</b> — rapidly progressive; associated with Yo, Tr (DNER, Hodgkin), mGluR1"), bullet_item("<b>Stiff-person syndrome</b> — progressive muscle rigidity, spasms; GAD65, amphiphysin antibodies"), bullet_item("<b>Opsoclonus-myoclonus</b> — chaotic eye movements + myoclonus; Ri antibodies, SCLC, neuroblastoma in children"), sp(6), ] # ── 5. DIAGNOSIS ───────────────────────────────────────────────────────────── story += [ h1("5. Diagnostic Work-Up"), body("Diagnosis requires a stepwise approach to exclude infectious/toxic causes, identify the specific autoantibody, and search for an underlying malignancy."), sp(4), ] diag_headers = [b("Step"), b("Investigation"), b("Purpose/Notes")] diag_rows = [ ["1", "Lumbar puncture + CSF analysis", "Lymphocytic pleocytosis (5–100/µL), elevated protein; send for antibody panel + culture + HSV PCR"], ["2", "Blood tests", "Autoantibody panel (serum + CSF); metabolic/toxic screen; thyroid (TPO abs); serum immunofixation"], ["3", "MRI brain with gadolinium", "Medial temporal FLAIR signal (limbic), diffuse cortical changes (NMDA-R); exclude mimics"], ["4", "EEG", "Seizures, extreme delta brush (NMDA-R), diffuse slowing"], ["5", "Malignancy screening", "CT chest/abdomen/pelvis; FDG-PET; pelvic US/MRI (teratoma); testicular US if Ma2+"], ["6", "Additional", "CSF cytology & flow cytometry; ophthalmology if visual symptoms; neuropsychological testing"], ] dw = [1.0*cm, 4.2*cm, 10.5*cm] story.append(make_table(diag_headers, diag_rows, col_widths=dw)) story += [ sp(6), note("⚠ Important: CSF antibody testing is more sensitive than serum for NMDA-R encephalitis. Always send both. In seronegative AE (up to ~50% of cases), diagnosis is based on Graus 2016 clinical criteria."), sp(6), ] # ── 6. TREATMENT ───────────────────────────────────────────────────────────── story += [ h1("6. Treatment"), body("No single standardized regimen exists. Treatment should be initiated <b>as early as possible</b> — early therapy hasten recovery and reduces disability and relapse risk. Stepwise escalation is used based on clinical response."), sp(4), h2("6a. First-Line Immunotherapy"), ] tx1_headers = [b("Agent"), b("Dose/Regimen"), b("Notes")] tx1_rows = [ ["IV Methylprednisolone", "1000 mg/day IV × 5 days", "First choice; continue with weekly dosing for 6–12 weeks"], ["IV Immunoglobulin (IVIg)", "400 mg/kg every other day × 5 days", "Use if steroids not tolerated; can be combined with steroids"], ["Plasma Exchange (PLEX)", "5–7 exchanges over 2 weeks", "For refractory disease or contraindications to other agents"], ] tw = [3.2*cm, 5.0*cm, 7.5*cm] story.append(make_table(tx1_headers, tx1_rows, col_widths=tw)) story += [sp(6), h2("6b. Second-Line Immunotherapy (if poor response to first-line)")] tx2_headers = [b("Agent"), b("Dose/Regimen"), b("Notes")] tx2_rows = [ ["Rituximab", "1000 mg IV × 2 doses, 2 weeks apart", "Anti-CD20; B-cell depletion; most evidence in NMDA-R encephalitis"], ["Tocilizumab", "4–8 mg/kg IV every 4 weeks", "Anti-IL-6 receptor; promising results in refractory cases"], ["Cyclophosphamide", "Variable", "Anecdotal reports; used in severe/refractory disease"], ] story.append(make_table(tx2_headers, tx2_rows, col_widths=tw)) story += [ sp(6), h2("6c. Maintenance / Long-Term Immunosuppression"), bullet_item("Oral prednisolone — tapered over weeks to months"), bullet_item("Azathioprine 2–3 mg/kg/day"), bullet_item("Mycophenolate mofetil 1–3 g/day"), bullet_item("Methotrexate — alternative option"), sp(4), h2("6d. Tumor Treatment"), body("For paraneoplastic AE, <b>prompt tumor treatment is essential</b> and often the most important step:"), bullet_item("Ovarian teratoma → surgical removal (laparoscopic oophorectomy)"), bullet_item("SCLC → chemotherapy ± radiation"), bullet_item("Thymoma → thymectomy"), bullet_item("Hodgkin lymphoma → ABVD chemotherapy"), sp(4), note("💊 Symptomatic treatment: Antiepileptics for seizures, benzodiazepines for agitation/catatonia, ICU monitoring for autonomic instability. Note: antipsychotics can worsen dyskinesias in NMDA-R encephalitis — use with caution."), sp(6), ] # ── 7. PROGNOSIS ───────────────────────────────────────────────────────────── story += [ h1("7. Prognosis"), ] prog_headers = [b("Antibody Type"), b("Prognosis"), b("Key Points")] prog_rows = [ ["Cell-surface antigens\n(NMDA-R, LGI1, CASPR2)", "Generally good with treatment", "Functional recovery possible; relapse risk exists (~12–25%); long-term immunosuppression may be needed"], ["Intracellular antigens\n(Hu, Yo, Ri, Ma2)", "Poor", "Neuronal death irreversible; limited response to immunotherapy; determined by tumor control"], ["GAD65", "Intermediate", "Partial response; often requires long-term immunosuppression"], ["Seronegative AE", "Variable", "Prognosis depends on clinical syndrome severity and speed of treatment"], ] pw = [3.8*cm, 3.0*cm, 8.9*cm] story.append(make_table(prog_headers, prog_rows, col_widths=pw)) story += [ sp(6), bullet_item("Early treatment consistently associated with better outcomes across all subtypes"), bullet_item("NMDA-R encephalitis: ~80% of patients show good recovery, but recovery may take months to years"), bullet_item("Relapse in NMDA-R encephalitis occurs in ~12–25%; more common when tumor is not found/treated"), sp(6), ] # ── 8. KEY DISTINGUISHING FEATURES ────────────────────────────────────────── story += [ h1("8. Key Distinguishing Clinical Clues"), sp(4), ] clue_headers = [b("Clinical Clue"), b("Think of...")] clue_rows = [ ["Young woman + psychiatric symptoms + orofacial dyskinesias", "Anti-NMDA-R encephalitis"], ["Brief, frequent ipsilateral face + arm jerks + hyponatremia", "Anti-LGI1 (FBDS)"], ["Encephalitis + insomnia + neuromyotonia + autonomic features", "Anti-CASPR2 (Morvan syndrome)"], ["Rapidly progressive cerebellar ataxia + breast/ovary cancer", "Anti-Yo (PCA-1)"], ["Encephalitis + SCLC + sensory neuropathy", "Anti-Hu (ANNA-1)"], ["Young man + diencephalic/brainstem encephalitis + testicular mass", "Anti-Ma2"], ["Encephalitis + rigidity + spasms + diabetes", "Anti-GAD65"], ["Encephalitis + diarrhea + hyperekplexia", "Anti-DPPX"], ["Encephalitis + refractory seizures + Hodgkin lymphoma", "Anti-mGluR5 (Ophelia syndrome)"], ["Sleep disorder + brainstem features + tau pathology", "Anti-IgLON5"], ["Post-HSV encephalitis recurrence/worsening", "Secondary anti-NMDA-R (triggered by HSV)"], ["Encephalitis + immune checkpoint inhibitor use", "Checkpoint-inhibitor-related AE"], ] cw2 = [8.0*cm, 7.7*cm] story.append(make_table(clue_headers, clue_rows, col_widths=cw2)) story.append(sp(10)) # ── FOOTER NOTE ────────────────────────────────────────────────────────────── story.append(hr()) footer_style = ParagraphStyle("Footer", fontSize=7.5, textColor=colors.HexColor("#94a3b8"), fontName="Helvetica-Oblique", alignment=TA_CENTER, leading=10) story.append(Paragraph( "Sources: Goldman-Cecil Medicine · Harrison's Principles of Internal Medicine 22E · Adams and Victor's Principles of Neurology 12E · " "Bradley and Daroff's Neurology in Clinical Practice · Plum & Posner's Stupor and Coma · " "Graus et al. Lancet Neurology 2016 (diagnostic criteria). Generated by Orris Medical Library.", footer_style )) # ── BUILD ──────────────────────────────────────────────────────────────────── doc.build(story) print(f"PDF saved: {OUTPUT}") PYEOF python3 /tmp/workspace/autoimmune-encephalitis/generate_pdf.py

Your PDF is ready. Here's the download link:

Autoimmune Encephalitis

PDF Document · PDF

What's included in the PDF:
  1. Definition & Epidemiology - incidence, demographics, checkpoint inhibitor association
  2. Pathogenesis - intracellular vs. cell-surface antigen antibodies, T-cell vs. antibody mechanisms
  3. Antibody Reference Table - 16 antibodies with tumor associations and clinical phenotypes
  4. Clinical Presentations - limbic encephalitis, NMDA-R encephalitis (staged), brainstem encephalitis, and specific syndromes (FBDS, stiff-person, opsoclonus-myoclonus)
  5. Diagnostic Work-Up - stepwise table (CSF, MRI, EEG, cancer screening)
  6. Treatment - first-line, second-line, maintenance, and tumor-specific management
  7. Prognosis - by antibody category
  8. Clinical Clues Table - quick reference matching presentation to antibody
This is a shared conversation. Sign in to Orris to start your own chat.